Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04909801 · ClinicalTrials.gov registry record · Phase 3

A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate

A Phase 3 study of Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb.

Active
Registry status
Phase 3
Development phase
338
Enrollment target
20
Study locations

NCT04909801 is a Phase 3 study of Rheumatoid Arthritis that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 338 participants, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04909801, a Phase 3 study of Rheumatoid Arthritis, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
338 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the superiority in efficacy of abatacept compared with adalimumab, on background methotrexate, in adults with early, seropositive, and shared epitope-positive rheumatoid arthritis and an inadequate methotrexate response.

Conditions Studied

Rheumatoid Arthritis

Interventions

  • DRUG Abatacept
  • DRUG Adalimumab
  • DRUG Methotrexate

Study Locations (20)

Buenos Aires

  • Local Institution - 0012 - CABA
  • Local Institution - 0016 - Quilmes
  • Local Institution - 0014 - San Isidro

California

  • Local Institution - 0036 - Fullerton
  • Local Institution - 0086 - Los Alamitos

Maryland

  • Local Institution - 0058 - Cumberland
  • Local Institution - 0038 - Hagerstown

Other

  • Local Institution - 0022 - Buenos Aires
  • Local Institution - 0023 - Buenos Aires

Colorado

  • Local Institution - 0041 - Aurora

Minnesota

  • Local Institution - 0084 - Eagan

New Jersey

  • Local Institution - 0040 - Freehold

New York

  • NYU Langone Ambulatory Care Brooklyn Heights - Brooklyn

Trial Details

FieldValue
Enrollment Target 338 participants
Start Date 2021-09-15
Est. Completion 2027-09-01
Phase Phase 3

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04909801

The ClinicalTrials.gov registry entry for NCT04909801 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 338 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (93% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 3 interventions - of which Abatacept is the first listed.

NCT04909801 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Buenos Aires, California, Maryland.

Frequently Asked Questions

What is clinical trial NCT04909801 about?

NCT04909801 is a clinical study titled "A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate". The purpose of this study is to evaluate the superiority in efficacy of abatacept compared with adalimumab, on background methotrexate, in adults with early, seropositive, and shared epitope-positive rheumatoid arthritis and an inadequate methotrexate response.

What is the current status of trial NCT04909801?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 338 participants. The study started on 2021-09-15. Estimated completion is 2027-09-01.

What conditions does trial NCT04909801 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT04909801?

The interventions under investigation include: Abatacept (DRUG), Adalimumab (DRUG), Methotrexate (DRUG).

Who is sponsoring clinical trial NCT04909801?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04909801 being conducted?

This trial has 20 study locations across California, Colorado, Maryland, Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rheumatoid Arthritis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.